edelfosine has been researched along with Black Fever in 4 studies
edelfosine: RN given refers to parent cpd
edelfosine : A racemate comprising equimolar amounts of (R)- and (S)-edelfosine.
1-octadecyl-2-methylglycero-3-phosphocholine : A glycerophosphocholine that is glycero-3-phosphocholine substituted at positions 1 and 2 by octadecyl and methyl groups respectively.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Castanys-Muñoz, E | 1 |
| Pérez-Victoria, JM | 1 |
| Gamarro, F | 1 |
| Castanys, S | 1 |
| Plano, D | 1 |
| Baquedano, Y | 1 |
| Moreno-Mateos, D | 1 |
| Font, M | 1 |
| Jiménez-Ruiz, A | 1 |
| Palop, JA | 1 |
| Sanmartín, C | 1 |
| Azzouz, S | 1 |
| Maache, M | 1 |
| Sarciron, ME | 1 |
| Petavy, AF | 1 |
| Osuna, A | 1 |
| Croft, SL | 1 |
| Snowdon, D | 1 |
| Yardley, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.[NCT00471705] | Phase 3 | 437 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Complete Clinical response: Initial cure plus the absence of recurrences or mucosal lesions for 6 months after the end of treatment.~Note: nitial cure: Complete re-epithelialization of all ulcers and complete disappearance of the induration up to 3 months after the end of treatment." (NCT00471705)
Timeframe: Until 6 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 85 |
| Glucantime® | 103 |
| Thermotherapy | 86 |
At least 50% increase in lesion size at the end of treatment, absence of clinical response at 6 weeks, or any sign of lesion activity 3 months after the end of treatment (NCT00471705)
Timeframe: Until 3 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 34 |
| Glucantime® | 14 |
| Thermotherapy | 42 |
Reactivation of the lesion at the original site after cure or mucosal compromise during follow-up. (NCT00471705)
Timeframe: Until 6 months post-treatment
| Intervention | Participants (Number) |
|---|---|
| Miltefosine | 3 |
| Glucantime® | 4 |
| Thermotherapy | 6 |
4 other studies available for edelfosine and Black Fever
| Article | Year |
|---|---|
Characterization of an ABCG-like transporter from the protozoan parasite Leishmania with a role in drug resistance and transbilayer lipid movement.
Topics: Aminoquinolines; Animals; Antiprotozoal Agents; ATP-Binding Cassette Transporters; Base Sequence; Bi | 2008 |
Selenocyanates and diselenides: a new class of potent antileishmanial agents.
Topics: Aminophenols; Animals; Antiprotozoal Agents; Cell Line, Tumor; Cyanates; Humans; Inhibitory Concentr | 2011 |
Study of the stress proteins secreted by Leishmania donovani after treatment with edelfosine, mitelfosine and ilmofosine, and morphological alterations analyzed by electronic microscopy.
Topics: Animals; Antineoplastic Agents; Autoradiography; Drug Resistance; Heat-Shock Proteins; Humans; Leish | 2009 |
The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei.
Topics: Animals; Antineoplastic Agents; Chagas Disease; Cricetinae; Female; Furans; Leishmania donovani; Lei | 1996 |